Literature DB >> 17131792

Repeated sputum microscopy is not essential for monitoring tuberculosis treatment response.

M Shivakumar1, B Prabhakarareddy, A Rajaprasannakumar, P Vijayakumaran, P Krishnamurthy.   

Abstract

SETTING: This study was conducted in two districts in India where DOTS has been implemented. There are 39 microscopy centres in Anantpur district and 34 in Nellore district (one per 100,000 population), each with a trained microscopist. Periodic follow-up sputum microscopy is performed for all tuberculosis (TB) patients on treatment, with two sputum specimens examined on each follow-up. Results are recorded in a laboratory register.
OBJECTIVE: To determine whether examining two sputum specimens for follow-up is useful for assessing treatment outcome.
DESIGN: A retrospective study using data from laboratory registers of all microscopy centres for 2002 in Anantpur and 2003 (January-June) in Nellore.
RESULTS: Of 5086 follow-up examinations done in Anantpur and 1028 in Nellore, 8% were acid-fast bacilli positive. One additional positive result was obtained on examination of a second sputum specimen. This result did not significantly add to the assessment of treatment outcome.
CONCLUSION: The yield of a second on-the-spot sputum specimen is negligible, provided that the first smear is from an overnight specimen. From the data available, it is evident that repeated follow-up smears are not essential for documenting treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17131792

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  1 in total

1.  Can follow-up examination of tuberculosis patients be simplified? A study in Chhattisgarh, India.

Authors:  Debashish Kundu; Ajay M V Kumar; Srinath Satyanarayana; Puneet Kumar Dewan; Sreenivas Achuthan Nair; Kshitij Khaparde; Priyakanta Nayak; Rafael Van den Bergh; Marcel Manzi; Donald A Enarson; Madhav Rao Deshpande; Sachin Chandraker
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.